KASL Clinical Practice Guidelines for Management of Chronic Hepatitis B

Overview

Journal Clin Mol Hepatol

Specialty Gastroenterology

Date 2022 Apr 17

PMID 35430783

Affiliations

Soon will be listed here.

Citing Articles

Comparison of hepatocellular carcinoma incidence after long-term treatment with besifovir vs. tenofovir AF.

Kim H, Kim J, Shin Y, Yoo H, Yoo J, Kim S Sci Rep. 2025; 15(1):5637.

PMID: 39955346 PMC: 11829943. DOI: 10.1038/s41598-025-89325-1.

Effect of invasive tests during pregnancy on perinatal transmission of hepatitis B infection: a scoping review.

Cheung K, Au T, Li Y, Han Z, Zhang Z, Seto M EClinicalMedicine. 2025; 80:103039.

PMID: 39885958 PMC: 11780714. DOI: 10.1016/j.eclinm.2024.103039.

Accelerating the momentum to achieve global elimination of hepatitis B infection: a scoping review of hepatitis B guidelines to reduce mother to child transmission.

Cheung K, Li Y, Au M, Seto M EClinicalMedicine. 2025; 80:103038.

PMID: 39877256 PMC: 11772972. DOI: 10.1016/j.eclinm.2024.103038.

Aetiology of chronic liver disease is a valuable factor for stratifying adverse outcomes of acute decompensation: prospective observational study.

Kim J, Kim S, Song D, Kim H, Yoon E, Park J Ann Med. 2025; 57(1):2428431.

PMID: 39856091 PMC: 11770857. DOI: 10.1080/07853890.2024.2428431.

Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation.

Lee S, Choi H, You Y, Sung P, Yoon S, Jang J Clin Mol Hepatol. 2024; 31(1):131-146.

PMID: 39355872 PMC: 11791583. DOI: 10.3350/cmh.2024.0451.

References

Yeo W, Johnson P . Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006; 43(2):209-20. DOI: 10.1002/hep.21051. View

Liu S, Zhang H, Gu C, Yin J, He Y, Xie J . Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst. 2009; 101(15):1066-82. PMC: 2720989. DOI: 10.1093/jnci/djp180. View

Liu W, Wang X, Zheng W, Ping L, Zhang C, Wang G . Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma. Leuk Lymphoma. 2016; 57(6):1355-62. DOI: 10.3109/10428194.2015.1116121. View

Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2015; 10(1):1-98. PMC: 4722087. DOI: 10.1007/s12072-015-9675-4. View

Yang W, Wu L, Tseng T, Chen C, Yang H, Su T . Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection. Medicine (Baltimore). 2016; 95(10):e2995. PMC: 4998890. DOI: 10.1097/MD.0000000000002995. View

de Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E . The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med. 1993; 118(3):191-4. DOI: 10.7326/0003-4819-118-3-199302010-00006. View

Yeo W, Chan T, Leung N, Lam W, Mo F, Chu M . Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2008; 27(4):605-11. DOI: 10.1200/JCO.2008.18.0182. View

Kim S, Yoon J, Lee M, Cho Y . Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus. Clin Mol Hepatol. 2021; 28(1):17-30. PMC: 8755466. DOI: 10.3350/cmh.2021.0093. View

Papatheodoridis G, Vlachogiannakos I, Cholongitas E, Wursthorn K, Thomadakis C, Touloumi G . Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology. 2016; 63(5):1481-92. DOI: 10.1002/hep.28438. View

10.

Triantos C, Kalafateli M, Nikolopoulou V, Burroughs A . Meta-analysis: antiviral treatment for hepatitis D. Aliment Pharmacol Ther. 2012; 35(6):663-73. DOI: 10.1111/j.1365-2036.2012.04993.x. View

11.

Chon Y, Kim S, Seo Y, Lee H, Lee H, Kim M . Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2021; 37(1):200-207. DOI: 10.1111/jgh.15678. View

12.

Kim G, Han S, Choi G, Choi J, Lim Y . Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. Aliment Pharmacol Ther. 2020; 51(11):1169-1179. DOI: 10.1111/apt.15725. View

13.

Chon H, Lee H, Suh S, Lee J, Kim B, Kim I . Addition of liver stiffness enhances the predictive accuracy of the PAGE-B model for hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2021; 53(8):919-927. DOI: 10.1111/apt.16267. View

14.

Shih C, Chen W, Yu H, Cheng J, Lai K, Hsu J . Risk of Severe Acute Exacerbation of Chronic HBV Infection Cancer Patients Who Underwent Chemotherapy and Did Not Receive Anti-Viral Prophylaxis. PLoS One. 2015; 10(8):e0132426. PMC: 4537229. DOI: 10.1371/journal.pone.0132426. View

15.

Chen C, Lee C, Lu S, Wang J, Tung H, Hung C . Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants. J Hepatol. 2004; 41(3):454-61. DOI: 10.1016/j.jhep.2004.04.032. View

16.

Jang J, Chun J, Park Y, Shin S, Yoo W, Kim S . Mutational complex genotype of the hepatitis B virus X /precore regions as a novel predictive marker for hepatocellular carcinoma. Cancer Sci. 2011; 103(2):296-304. DOI: 10.1111/j.1349-7006.2011.02170.x. View

17.

Gwak G, Huh W, Lee D, Min B, Koh K, Kim J . Occult hepatitis B virus infection in chronic hemodialysis patients in Korea. Hepatogastroenterology. 2008; 55(86-87):1721-4. View

18.

Wong D, Seto W, Cheung K, Chong C, Huang F, Fung J . Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int. 2016; 37(7):995-1001. DOI: 10.1111/liv.13346. View

19.

Sagnelli E, Pasquale G, Coppola N, Scarano F, Marrocco C, Scolastico C . Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection. 2004; 32(3):144-8. DOI: 10.1007/s15010-004-3080-6. View

20.

Yip T, Wong G, Wong V, Tse Y, Lui G, Lam K . Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. J Hepatol. 2017; . DOI: 10.1016/j.jhep.2017.09.018. View